Trials / Withdrawn
WithdrawnNCT04704843
A Study of Guselkumab in Adult Participants With Celiac Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Response of Guselkumab in Adult Participants With Celiac Disease
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of guselkumab compared to placebo in participants with celiac disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab will be administered as IV infusion (induction dose) and SC injection. |
| DRUG | Placebo | Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection. |
Timeline
- Start date
- 2021-06-17
- Primary completion
- 2021-09-13
- Completion
- 2021-09-13
- First posted
- 2021-01-12
- Last updated
- 2025-02-03
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04704843. Inclusion in this directory is not an endorsement.